bluebird bio, Inc. Forecast, price target & analysts
bluebird bio, Inc. Target price 2025 - Analyst rating & recommendation
bluebird bio, Inc. Classifications & Recommendation:
bluebird bio, Inc. Price Target
| Target Price | $8.00 |
| Price | $4.98 |
| Potential |
60.64%
register free of charge
|
| Number of Estimates | 2 |
|
2 Analysts have issued a price target bluebird bio, Inc. 2026 .
The average bluebird bio, Inc. target price is $8.00.
This is
60.64%
register free of charge
$8.00
60.64%
register free of charge
$8.00
60.64%
register free of charge
|
|
| A rating was issued by 3 analysts: 1 Analysts recommend bluebird bio, Inc. to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the bluebird bio, Inc. stock has an average upside potential 2026 of
60.64%
register free of charge
|
Sales and Margin forecast 2025, 2026 & 2027
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 83.81 | 249.90 |
| 184.10% | 198.17% | |
| EBITDA Margin | -246.34% | -65.19% |
| 76.46% | 73.54% | |
| Net Margin | -290.16% | -45.35% |
| 77.34% | 84.37% |
3 Analysts have issued a sales forecast bluebird bio, Inc. 2025 . The average bluebird bio, Inc. sales estimate is
This results in the following potential growth metrics:
2 Analysts have issued an bluebird bio, Inc. EBITDA forecast 2025. The average bluebird bio, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2024 | $-206m | 33.11% |
|---|---|---|
| 2025 |
$-163m
21.09%
Unlock
|
|
EBITDA Margin
| 2024 | -246.34% | 76.46% |
|---|---|---|
| 2025 |
-65.19%
73.54%
Unlock
|
|
4 bluebird bio, Inc. Analysts have issued a net profit forecast 2025. The average bluebird bio, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 & 2027
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -24.84 | -11.58 |
| 35.63% | 53.38% | |
| P/E | negative | |
| EV/Sales | 0.63 |
4 Analysts have issued a bluebird bio, Inc. forecast for earnings per share. The average bluebird bio, Inc. EPS is
This results in the following potential growth metrics and future valuations:
bluebird bio, Inc....
Current bluebird bio, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Barclays |
Locked
➜
Locked
|
Locked | Mar 31 2025 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Feb 24 2025 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Feb 24 2025 |
| Barclays |
Locked
➜
Locked
|
Locked | Dec 31 2024 |
| B of A Securities |
Locked
➜
Locked
|
Locked | Nov 15 2024 |
| Barclays |
Locked
➜
Locked
|
Locked | Nov 15 2024 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Nov 15 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Barclays:
Locked
➜
Locked
|
Mar 31 2025 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Feb 24 2025 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Feb 24 2025 |
|
Locked
Barclays:
Locked
➜
Locked
|
Dec 31 2024 |
|
Locked
B of A Securities:
Locked
➜
Locked
|
Nov 15 2024 |
|
Locked
Barclays:
Locked
➜
Locked
|
Nov 15 2024 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Nov 15 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
